Biovestin-lacto emulsion, 12 ml 7 pcs.
€15.00 €13.00
Biovestin-lacto is a complex probiotic. It contains in its composition bifido- and lactobacteria – representatives of normal human microflora.
Biovestin-lacto contains strain of Bifidobacterium adolescentis MC-42 with high antagonistic activity against conditionally pathogenic and pathogenic microorganisms and resistance to therapeutic doses of the most common antibiotics.
Because the harmful environmental factors (increased radiation, stress, use of chemicals in the food industry, antibiotics and other chemopreparations in medicine) usually kill all representatives of normoflora, the product Biovestin-lacto includes lactobacilli along with bifidobacteria. The pharmacopoeial strain known for its positive properties in the treatment of human dysbiosis – Lactobacillus plantarum – is used.
The presence of several different microorganisms in Biovestin-Lacto increases the range of application of this product and increases the effect of this dietary supplement.
The possibility of using Biovestin-lacto in combination therapy for intestinal dysfunctions (diarrhea as a clinical manifestation of dysbiosis); dysbacteriosis of various origins caused by the presence of conditionally pathogenic intestinal microflora, for the correction of the microflora of exposed nasopharyngeal mucosa During pregnancy, during prenatal preparation, prolonged hormonal and radiation therapy, respiratory infections and their prevention, various manifestations of food allergies, iron deficiency anemia, vitamin deficiency states.
Biovestin-lacto is compatible with drugs, including antibiotics.
Indications
Dysbacteriosis, Intestinal infections, Diarrhea, After a course of antibiotic therapy
Biovestin-lacto should be used to protect the intestinal microflora when using antibiotics and other antibacterial drugs.
In addition, Biovestin-lacto should be used in combination therapy for:
- intestinal dysfunction (diarrhea, as a clinical manifestation of dysbiosis);
- Dysbacteriosis of various origins due to the presence of conditionally pathogenic and pathogenic intestinal microflora;
- correction of the microflora of open mucous membranes (oral cavity);
- prenatal preparation;
- long-term hormonal and radiation therapy;
- respiratory infections and their prevention;
- food allergies
- iron anemia, vitamin deficiency, rickets
- bacterial vaginosis
.
Composition
1 bottle of emulsion for oral administration contains:
the active ingredients:
Bifidobacterium adolescentis (109 CFU/ml);
Lactobacillus plantarum (108 CFU/ml);
Bifidogenic factors and metabolic products of bifido- and lactobacilli.
How to take, the dosage
Biovestin-lacto should preferably be taken 30 minutes before a meal, so that its evacuation from the stomach to the lower intestine as quickly as possible. For a more comfortable intake it is possible to dilute a single dose in boiled chilled water, milk or juice.
Biovestin-lacto is compatible with all medications, including antibiotics. Administration does not require withdrawal of medicines. If dysbacteriosis caused by a lack of bifidobacteria and lactobacilli is eliminated, the course of Biovestin-lacto intake is 2 weeks.
In order to protect normal intestinal microflora while taking antibiotics, the course of treatment is the entire period of taking antibiotics.
Daily doses of Biovestin:
– children under 1 year – up to 1 ml per day;
– children from 1 to 12 years – up to 6 ml per day;
– adults – up to 12 ml per day.
Biovestin-lacto is absolutely physiological for humans and its overdose is not dangerous.
Contraindications
- individual intolerance to the product components
- intolerance of milk protein.
Pregnancy use
Biovestin-lacto can be given to children from 1 year old.
Weight | 0.188 kg |
---|---|
Shelf life | 2 months. |
Conditions of storage | At a temperature of 2-6 °C. Keep out of reach of children. |
Manufacturer | BioVesta, Russia |
Medication form | oral emulsion |
Brand | BioVesta |
Related products
Buy Biovestin-lacto emulsion, 12 ml 7 pcs. with delivery to USA, UK, Europe and over 120 other countries.